Cargando…
Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892947/ https://www.ncbi.nlm.nih.gov/pubmed/29662320 http://dx.doi.org/10.2147/JAA.S107982 |
_version_ | 1783313238916595712 |
---|---|
author | Tabatabaian, Farnaz Ledford, Dennis K |
author_facet | Tabatabaian, Farnaz Ledford, Dennis K |
author_sort | Tabatabaian, Farnaz |
collection | PubMed |
description | Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as inflammation associated with atopy or eosinophilia or an increase in cytokines associated with T-helper 2 lymphocytes. Omalizumab is a humanized anti-IgE monoclonal antibody and the first biologic therapy approved for moderate–severe allergic asthma. Despite the specificity of biologic therapies like omalizumab, clinical response is variable, with approximately 50% of treated patients achieving the primary outcome. A prior identification of the ideal candidate for therapy would improve patient outcomes and optimize the use of health care resources. As the number of biologic therapies for asthma increases, the goal is identification of biomarkers or clinical phenotypes likely to respond to a specific therapy. This review focuses on potential biomarkers and clinical history that may identify responders to omalizumab therapy for asthma. |
format | Online Article Text |
id | pubmed-5892947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58929472018-04-16 Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history Tabatabaian, Farnaz Ledford, Dennis K J Asthma Allergy Review Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as inflammation associated with atopy or eosinophilia or an increase in cytokines associated with T-helper 2 lymphocytes. Omalizumab is a humanized anti-IgE monoclonal antibody and the first biologic therapy approved for moderate–severe allergic asthma. Despite the specificity of biologic therapies like omalizumab, clinical response is variable, with approximately 50% of treated patients achieving the primary outcome. A prior identification of the ideal candidate for therapy would improve patient outcomes and optimize the use of health care resources. As the number of biologic therapies for asthma increases, the goal is identification of biomarkers or clinical phenotypes likely to respond to a specific therapy. This review focuses on potential biomarkers and clinical history that may identify responders to omalizumab therapy for asthma. Dove Medical Press 2018-04-03 /pmc/articles/PMC5892947/ /pubmed/29662320 http://dx.doi.org/10.2147/JAA.S107982 Text en © 2018 Tabatabaian and Ledford. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Tabatabaian, Farnaz Ledford, Dennis K Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title | Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title_full | Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title_fullStr | Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title_full_unstemmed | Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title_short | Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
title_sort | omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892947/ https://www.ncbi.nlm.nih.gov/pubmed/29662320 http://dx.doi.org/10.2147/JAA.S107982 |
work_keys_str_mv | AT tabatabaianfarnaz omalizumabforsevereasthmatowardpersonalizedtreatmentbasedonbiomarkerprofileandclinicalhistory AT ledforddennisk omalizumabforsevereasthmatowardpersonalizedtreatmentbasedonbiomarkerprofileandclinicalhistory |